The Manufacturers Life Insurance Company Has $30.55 Million Holdings in Revvity Inc. $RVTY

The Manufacturers Life Insurance Company boosted its holdings in Revvity Inc. (NYSE:RVTY – Free Report) by 7.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 348,660 shares of the company’s stock after acquiring an additional 23,509 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Revvity were worth $30,546,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Ascentis Independent Advisors purchased a new stake in shares of Revvity in the first quarter worth approximately $29,000. CYBER HORNET ETFs LLC bought a new position in shares of Revvity in the second quarter valued at approximately $32,000. Cromwell Holdings LLC boosted its position in shares of Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after buying an additional 198 shares during the last quarter. MUFG Securities EMEA plc purchased a new position in shares of Revvity during the second quarter valued at approximately $34,000. Finally, SJS Investment Consulting Inc. grew its holdings in Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after buying an additional 521 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Get Revvity alerts:

Revvity Stock Performance

Shares of RVTY opened at $112.79 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $12.58 billion, a price-to-earnings ratio of 53.96, a PEG ratio of 2.23 and a beta of 1.09. The stock has a 50 day moving average of $106.51 and a 200 day moving average of $99.91. Revvity Inc. has a 12 month low of $81.22 and a 12 month high of $118.30.

Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The business had revenue of $711.12 million for the quarter, compared to analysts’ expectations of $704.07 million. During the same quarter in the previous year, the firm earned $1.01 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, sell-side analysts forecast that Revvity Inc. will post 5.25 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on RVTY. JPMorgan Chase & Co. lowered their price target on Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Barclays lifted their price objective on shares of Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Zacks Research lowered shares of Revvity from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Wolfe Research started coverage on shares of Revvity in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Finally, Robert W. Baird set a $117.00 price target on shares of Revvity in a research report on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $108.36.

Read Our Latest Report on RVTY

About Revvity

(Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

See Also

• Five stocks we like better than Revvity
• Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
• Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
• Apple’s Record Quarter Could Not Outrun Its Guidance Problem
• McKesson’s Compounding Keeps Adding Up

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY – Free Report).

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.